PIP5K1A and cancer: The immunoblot analysis revealed a dose-dependent decrease in PIP5K1α expression in DLD1 and CT26 cancer cells treated with MakA for 48 h, essentially similar to the effect found in HCT8 cells (Fig. 3C, D and Fig. S2A, B).